Clinical trials: Patients with Advanced Solid Tumors
Male Breast Cancer, Recurrent Bladder Cancer
Decitabine in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment.
- Conditions
- Male Breast Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Melanoma
- Trial name
- NCT00030615
- Testing
- decitabine, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A Study of NBL-028 in Patients With Advanced Solid Tumors
This is a multi-center, single agent study conducted in patients with advanced solid tumor types known to express Claudin 6 (CLDN6) for whom standard of care therapies are not available, are no longer effective, or not tolerated.
- Trial name
- NCT06223256
- Testing
- NBL-028
- Where
- China
- Volunteers
- 270 people
- Sponsor
- NovaRock Biotherapeutics, Ltd
Advanced Solid Tumors
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.
- Trial name
- NCT05830045
- Testing
- QLP2117
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumors
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
Ridaforolimus (Deforolimus, AP23573, MK-8669) is an mTor inhibitor shown to have promising activity in adults with a variety of solid malignancies, particularly the sarcomas.
- Trial name
- NCT00704054
- Testing
- ridaforolimus
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
This is a phase I, open-label, multi-center, dose escalation and expansion study in advanced or metastatic solid tumor patients.
- Trial name
- NCT07260305
- Testing
- KGX101 injection, Envafolimab
- Where
- 3 sites in China
- Volunteers
- 57 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Unspecified Adult Solid Tumor, Protocol Specific
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
This randomized phase I trial studies the side effects and best dose of nanosomal docetaxel lipid suspension in treating patients with advanced solid tumors.
- Trial name
- NCT01957995
- Testing
- nanosomal docetaxel lipid suspension, pharmacological study
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Southern California
MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Evaluation of XYA02 in Patients With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
- Conditions
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma
- Trial name
- NCT07670312
- Testing
- XYA02
- Where
- 5 sites in Australia
- Volunteers
- 190 people
- Sponsor
- XYone Therapeutics, Inc
Advanced/Metastatic Solid Tumors
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
- Trial name
- CLINCH (NCT05718895)
- Testing
- ATG-022
- Where
- 22 sites in Australia, China
- Volunteers
- 156 people
- Sponsor
- Antengene Biologics Limited
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Pancreatic Neoplasms, Ovarian Neoplasms
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
This is a phase 1, Open-label, multicenter Dose Escalation study of BTP-114, a novel platinum product, in patients with advanced solid tumors and BRCA or other DNA repair mutation.
- Conditions
- Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT02950064
- Testing
- BTP-114
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Placon Therapeutics
Lymphoma, Non-Hodgkin
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
To determine the safety and tolerability of CC-122 when administered orally to adult Japanese subjects with advanced solid tumors or Non-Hodgkin's Lymphoma (NHL) and to define the maximum tolerated dose (MTD) and/or recommended…
- Trial name
- NCT02509039
- Testing
- CC-122
- Where
- 3 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Celgene
Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
This trial is an open, multicenter, phase II clinical trial to evaluate the efficacy and safety of Utidelone capsules in patients with advanced solid tumors.
- Conditions
- Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer, Bile Duct Cancer
- Trial name
- NCT06730581
- Testing
- Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule
- Volunteers
- 100 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Liver Cancer, Lung Cancer
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of ipilimumab and stereotactic body radiation therapy (SBRT).
- Trial name
- NCT02239900
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
- Trial name
- NCT05866692
- Testing
- TY-2699a
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- TYK Medicines, Inc
Advanced Solid Tumor, HER2-negative Breast Cancer
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
- Trial name
- NCT06334432
- Testing
- NUV-1511
- Where
- 8 sites in United States
- Volunteers
- 466 people
- Sponsor
- Nuvation Bio Inc.
Conditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor
UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors
This is a single-arm, open, early-stage clinical study. The main purpose of this study is to explore the maximum tolerated dose (MTD), the optimal phase II recommended dose, safety, initial anti-tumor activity…
- Trial name
- NCT06372236
- Testing
- UTAA06 injection for treatment of advanced malignant solid tumors
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University
Advanced or Metastatic Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid…
- Trial name
- NCT06752681
- Testing
- DAY301
- Where
- 11 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Metastatic or Unresectable Solid Tumor Malignancy
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors.
- Trial name
- NCT01226732
- Testing
- Capecitabine, Hsp90 Inhibitor AUY 922
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- SCRI Development Innovations, LLC
Solid Tumor
Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the safety/tolerability、the pharmacokinetic profile and efficacy of HS-10365 in Chinese advanced solid tumor…
- Trial name
- NCT05207787
- Testing
- HS-10365
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumors
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
This phase Ib trial studies the best dose and side effects of alpelisib and cisplatin in treating patients with human papillomavirus (HPV) positive solid tumor malignancies.
- Trial name
- NCT02620839
- Testing
- Alpelisib, Cisplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Pamela Munster
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.